Table III.
Outcomes for the comparison of remote care versus inpatient care in patients with atopic dermatitis
| Study | Safety | Disease severity score (mean difference [95% CI]) | Quality of life scores | Patient and caretaker satisfaction | Costs and cost-efficiency | Mobility | Length and frequency of consultation |
|---|---|---|---|---|---|---|---|
| Armstrong, 2015 (22, 23, 25) Follow-up 12 months |
Not reported | POEM: 0.24 (SD 6.59) [90% CI −1.70 to 1.23] IGA: 5.1% [90% CI 1.7%–8.6%] |
CDLQI: 0.23 [90% CI, –2.21 to 2.67], DLQI: 0.72 [90% CI, –0.97 to 2.41] SF-12 PCS: 0.34 [90% CI, –1.16 to 1.84] SF-12 MCS: 0.51 [90% CI, –1.11 to 2.13] |
Not investigated | Not investigated | Not investigated | Not investigated |
|
| |||||||
| Bergmo, 2009 (19) Follow-up 12 months |
Not reported | SCORAD: no interaction between the groups (p = 0.55) | Not investigated | Not investigated | Not investigated | Not investigated | Not investigated |
|
| |||||||
| Van Os-Medendorp, 2012 Follow-up 12 months (16) |
Not reported | P for interaction of disease severity (p = 0.04; however, at each time point no significant differences), Extent and severity of AD (p = 1.00) |
DLQI (p = 0.45) | Not investigated | Direct costs: €24 [95% CI –360 to 383], Indirect costs: –€618 [95% CI –2502 to 1,143] Total costs –€594 [95% CI –2545 to 1,227] per patient |
Not investigated | Not investigated |
AD: atopic dermatitis; (C)DLQI: (Children’s) Dermatology Life Quality Index; CI: confidence interval; IGA: Investigator Global Assessment; POEM: Patient-Oriented Eczema Measure; SCORAD: Severity Scoring of Atopic Dermatitis; SD: standard deviation; SF-12 PCS/MCS: Short Form Physical Component Score/Mental Component Score; VAS: visual analogue scale.